Purchase Order 75N98026P01737

The National Cancer Institute issued a purchase order to Coherent NA, Inc. for $34,674.50 on August 5, 2026, for an OBIS 304NM XT 40MW laser system, with ultimate completion by August 4, 2027. The order references quote COHR-395680-1 and carries firm fixed-price pricing on a full-and-open basis with no set-aside. Work is performed at Coherent NA's Santa Clara, California facility. The laser system is a specialized optical instrument for NCI research operations; Coherent NA manufactures and...

<p>The National Cancer Institute awarded a purchase order to Coherent Inc. for $133,380.00 on September 28, 2017, with an ultimate completion date of November 16, 2017. The order is firm fixed-price with no small business set-aside. Performance takes place in Santa Clara, California. The source does not specify the laser systems or equipment being purchased.</p>

<p>The National Cancer Institute awarded a purchase order to Coherent Inc. for $19,190 on July 25, 2018, for a maintenance agreement on a Coherent laser group system. Performance is located in Santa Clara, California, with an ultimate completion date of July 24, 2019. The order is firm fixed-price; no set-aside was used.</p>

<p>The National Cancer Institute awarded a purchase order to Coherent Inc. for $7,072.75 on July 2, 2018, with an ultimate completion date of August 2, 2018. The order is a firm fixed-price acquisition with no set-aside designation. Place of performance is Bethesda, Maryland. The procurement is for coherent laser group equipment and services [18-046094], typical of the vendor's federal portfolio of precision laser systems and related instrumentation for scientific research applications.</p>

<p>The National Institute of Biomedical Imaging and Bioengineering awarded a purchase order to Coherent Inc. for $22,837.30 on March 13, 2018, covering three coherent lasers: an OBIS 405NM LX 100MW laser, an OBIS 488NM LS 150MW laser, and an OBIS 561NM LS 150MW laser. Performance occurs at Bethesda, Maryland, with completion required by April 30, 2018. The order carries firm fixed pricing and uses no small business set-aside.</p>

<p>The National Cancer Institute awarded a purchase order to Coherent Inc. on December 18, 2017, with a ceiling value of $5,566.05 and an ultimate completion date of December 28, 2018. The order is firm fixed price with no set-aside. Place of performance is Bethesda, Maryland.</p>

<p>The National Institute of Biomedical Imaging and Bioengineering awarded a purchase order to Coherent Inc. for a Coherent 488 nm laser and 561 nm OBIS laser, valued at $15,440.00, with an award date of July 17, 2017. The order carries no set-aside designation. Place of performance is Bethesda, Maryland. The ultimate completion date is October 17, 2017.</p>

<p>The National Human Genome Research Institute awarded a purchase order to Coherent Inc. for $10,528.00 on September 10, 2019, for an OBIS 561NM LS 150MW laser (Part #1280720). The order carries a firm fixed price and ultimate completion date of October 10, 2019. Work is performed in Santa Clara, California.</p>

<p>The National Cancer Institute issued a purchase order to Modulight USA, Inc. for one CE/ETL medical laser system valued at $58,700.00, awarded August 7, 2017, with completion due October 30, 2017. Place of performance is Bethesda, Maryland. The procurement is for a single medical laser system under firm fixed price terms.</p>

<p>The National Cancer Institute awarded a purchase order to Coherent Inc. for $8,800.00 on January 18, 2018, with completion scheduled for February 11, 2019. Place of performance is Bethesda, Maryland. The order is firm fixed price with no small business set-aside.</p>